Report of the cent gardes HIV vaccine conference the B-cell response to HIV. Part 1: Broadly neutralizing antibodies fondation mérieux conference center, Veyrier du Lac, France, 5-7 November 2012

Vaccine

Volumn 31, Issue 29, 2013, Pages 2979-2983

  Girard, Marc P ^a   Picot, Valentina ^b   Longuet, Christophe ^b   Nabel, Gary J ^c  

^a ACADÉMIE NATIONALE DE MÉDECINE   (France)

^b Fondation Mérieux ^*  (France)

^c SANOFI   (United States)

Author keywords

B cell maturation; Broadly neutralizing antibodies; HIV Vaccines; Vectored immunoprophylaxis

Indexed keywords

ANTIGEN; BROADLY NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; NON NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; B LYMPHOCYTE ACTIVATION; CELL MATURATION; DRUG DESIGN; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; FRANCE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; MACACA; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

EID: 84879013294     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.068     Document Type: Review

References (36)

1. Walker L.M., Burton D.R. Rational antibody-based HIV-1 design: current approaches and future directions. Curr. Opin. Immunol. 2010, 22:358-366.
2. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchat R., Julien J.-P., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
3. Burton D.R., Poignard P., Stanfield R.L., Wilson I.A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012, 337:183-186.
4. Phogat S., Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr. Pharm. Des. 2007, 13:213-227.
5. Hu S.L., Stamatatos L. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr. HIV Res. 2007, 5:507-513.
6. Kwong P.D., Mascola J.R., Nabel G.J. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb. Perspect. Med. 2011, 1:a007278.
7. Johnson P.R., Schnepp B.C., Zhang J., Connell M.J., Greene S.M., Yuste E., et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nature Med. 2011, 15:901-906.
8. Balazs A.B., Chen J., Hong C.M., Rao D.S., Yang L., Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012, 481:81-84.
9. Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.
10. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.-P., Khayat R., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
11. Kwong P.D., Mascola J.B. Human antibodies that neutralize HIV-1: identification, structures and B cell ontogenies. Immunity 2012, 37:412-425.
12. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.
13. Li Y., O'Dell S., Wilson R., Schmidt S.D., Hogerkorp C.M., Louder M.K., et al. HIV-1 neutralizing antibodies display dual recognition of the primary and coereceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J. Virol. 2012, 86:11231-11241.
14. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.-S., Wang S.-K., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
15. Moore P.L., Gray E.S., Wibmer C.K., Bhiman J.N., Nonyane M., Sheward D.J., et al. Evolution of a glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 2012, 18:1688-1692.
16. Huang J., Ofek G., Laub L., Louder M.K., Doria-Rose N.A., Longo N.S., et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491:406-412.
17. Briney B.S., Willis J.R., Crowe J.E. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS ONE 2012, 7(5):e36750.
18. Briney B.S., Willis J.R., Hicar M.D., Thomas J.W., Crowe J.E. Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire. Immunology 2012, 137:56-64.
19. Planque S.A., Mitsuda Y., Nishiyama Y., Karle S., Boivin S., Salas M., et al. Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine. J. Immunol. 2012, 189:5367-5381.
20. Verkoczy L., Diaz M., Holl T.M., Ouyang Y.B., Bouton-Verville H., Alam S.M., et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunological tolerance. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:181-186.
21. Schmidt E., Zillikens D. Pemphigoid disease. Lancet 2013, 381:320-332.
22. Kobie J.J., Alcena D.C., Zheng B., Bryk P., Mattiaccio J.L., Brewer M., et al. 9G4 autoreactivity is increased in HIV-infected patients and correlatos with HIV broadly neutralizing serum activity. PLoS ONE 2012, 7:e33356.
23. Lynch R.M., Tran L., Louder M.K., Schmidt S.D., Cohen M., CHAVI 001 Clinical Team Members, et al. The development of CD4 binding site antibodies durig HIV-1 infection. J. Virol. 2012, 86:7588-7595.
24. McCoy L.E., Quigley A.F., Strokappe N.M., Bulmer-thomas B., Seaman M.S., Mortier D., et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 2012, 209:1091-1103.
25. Hinz A., Lutje Hulsik D., Forsman A., Forsman A., Koh W.W., Belrhali H., et al. Crystal structure of the neutralizing Llama V(HH)D7 and its mode of HIV-1 gp120 interaction. PLoS ONE 2010, 5:e10482.
26. Walker L.M., Sok D., Nishimura Y., Donau O., Sadjadpour R., Gautam R., et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Nat. Acad. Sci. U.S.A. 2011, 108:20125-20129.
27. Klein F., Stromberg A.H., Horwitz J.A., Gruell H., Scheid J.F., Bournazos S., et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492:118-122.
28. Ofek G., Guenaga F.J., Schief W.R., Skinner J., Baker D., Wyatt R., Kwong P.D. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Nat. Acad. Sci. U.S.A. 2010, 107:17880-17887.
29. Correia B.E., Ban Y.E., Holmes M.A., Xu H., Ellingson K., Kraft Z., et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 2010, 18:1116-1126.
30. Ye L., Wen Z., Dong K., Wang X., Bu Z., Zhang H., et al. Induction of HIVneutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines. PLoS ONE 2011, 6(5):e14813.
31. Kovacs J.M., Nkolota J.P., Peng H., Cheung H., Perry J., Miller C.A., et al. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc. Nat. Acad. Sci. U.S.A. 2012, 109:12111-12116.
32. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482:89-93.
33. Geall A.J., Verma A., Otten G.R., Shaw C.A., Hekele A., Banerjee K., et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Nat. Acad. Sci. U.S.A. 2012, 109:14604-14609.
34. Girard MP, Picot V, Longuet C, Nabel GJ. Report of the Cent Gardes HIV vaccine conference "the B-cell response to HIV". Part 2: Non-neutralizing antibodies. Fondation Merieux Conference Center, Veyrier-du-Lac, France, 5-7 November 2012. Vaccine; in press.
35. Hessell A.J., Haigwood N.L. Neutralizing antibodies and control of HIV: moves and countermoves. Curr. HIV/AIDS Rep. 2012, 9:64-72.
36. Briney B.S., Willis J.R., McKinney B.A., Crowe J.E.jr. High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals. Genes Immun. 2012, 13:469-473.